Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ANA APARICIO and SUMIT K. SUBUDHI.
ANA APARICIO
Connection Strength
1.567
SUMIT K. SUBUDHI
  1. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-na?ve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer. 2021 10; 9(10).
    View in: PubMed
    Score: 0.210
  2. RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer. J Immunother Precis Oncol. 2020 Aug; 3(3):128-132.
    View in: PubMed
    Score: 0.190
  3. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020 04 01; 12(537).
    View in: PubMed
    Score: 0.189
  4. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019 10; 20(10):1432-1443.
    View in: PubMed
    Score: 0.182
  5. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A. 2016 10 18; 113(42):11919-11924.
    View in: PubMed
    Score: 0.148
  6. Immune Checkpoint Therapies in Prostate Cancer. Cancer J. 2016 Mar-Apr; 22(2):117-20.
    View in: PubMed
    Score: 0.142
  7. Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series. Clin Cancer Res. 2024 Mar 15.
    View in: PubMed
    Score: 0.062
  8. Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experience. Cardiooncology. 2023 Sep 13; 9(1):33.
    View in: PubMed
    Score: 0.060
  9. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-na?ve prostate cancer. Eur J Cancer. 2021 11; 157:259-267.
    View in: PubMed
    Score: 0.052
  10. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open. 2021 08 02; 4(8):e2122998.
    View in: PubMed
    Score: 0.052
  11. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer. 2021 07; 9(7).
    View in: PubMed
    Score: 0.051
  12. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2021 02; 19(1):22-31.e5.
    View in: PubMed
    Score: 0.048
  13. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2020 03; 127:67-75.
    View in: PubMed
    Score: 0.047
  14. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Na?ve Metastatic Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):990-999.
    View in: PubMed
    Score: 0.047
  15. Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. Cell. 2019 Nov 14; 179(5):1177-1190.e13.
    View in: PubMed
    Score: 0.046
  16. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest. 2018 08 31; 128(9):3813-3818.
    View in: PubMed
    Score: 0.042
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.